TMCnet News

Research and Markets: Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
[May 07, 2014]

Research and Markets: Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/4ff2rq/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles/records featured in thereport undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.



Companies Involved:

  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • California Stem Cell, Inc.
  • Cell Therapeutics, Inc.
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Daiichi Sankyo Company, Limited
  • EGEN, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • ImmunoGen, Inc.
  • Immunovaccine, Inc.
  • Incyte Corporation
  • Lee's Pharmaceutical Holdings Limited
  • MEI Pharma, Inc.
  • MabVax Therapeutics, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OncoMed Pharmaceuticals, Inc.
  • Oncolytics Biotech Inc.
  • Oxford BioMedica plc
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • Recepta Biopharma S.A.
  • Spectrum (News - Alert) Pharmaceuticals, Inc.
  • Synta Pharmaceuticals Corp.
  • TRION Pharma GmbH

Drug Profiles:


  • pazopanib hydrochloride
  • trebananib
  • paclitaxel poliglumex
  • paclitaxel
  • MEK-162
  • idronoxil
  • trabectedin
  • alisertib
  • dalantercept
  • elesclomol
  • TroVax
  • ramucirumab
  • pelareorep
  • nintedanib
  • catumaxomab
  • CRLX-101
  • VTX-2337
  • gimatecan
  • exatecan mesylate
  • RebmAb-100
  • EGEN-001
  • NSC-748933
  • INCB-24360
  • birinapant
  • rucaparib
  • metformin
  • Cancer Stem Cell Therapy
  • DPX-Survivac
  • ganetespib
  • pralatrexate

For more information visit http://www.researchandmarkets.com/research/4ff2rq/fallopian_tube


[ Back To TMCnet.com's Homepage ]